The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ERIC 2018 | A perspective on the current landscape of CLL treatment
Eva Kimby, MD, PhD, of the Karolinska University Hospital, Solna, Sweden, discusses her thoughts on the current landscape of CLL treatment. Prof. Kimby covers the different therapeutic options available, including FCR chemotherapy, bendamustine, monoclonal antibodies and ibrutinib, considering the patient’s biomarker status, age and fitness. She also discusses considerations surrounding the use of ibrutinib in younger patients, expressing that long-term follow ups are still awaited. This video was recorded at the European Research Initiative on CLL (ERIC) International Meeting 2018, held in Barcelona, Spain.
